Clinical Trial Update: Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine [Phase 1]

View source ↗

Summary

The Phase 1 clinical trial evaluating reduction of demoralization in patients with tardive dyskinesia after treatment with valbenazine has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• Valbenazine (valbenazine)

Snippet

Sponsor: Yale University | Conditions: Tardive Dyskinesia | Phase 1 | Status: WITHDRAWN